Selecting the neoadjuvant treatment by molecular subtype: How to maximize the benefit?

Breast

Volumn 22, Issue S2, 2013, Pages

  Von Minckwitz, Gunter ^a,b,c   Fontanella, Caterina ^a,d  

^a GERMAN BREAST GROUP   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Senologic Oncology   (Germany)

^d UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Breast cancer; Neoadjuvant treatment; Pathologic complete response; Tumor subtype

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; EVENT FREE SURVIVAL; HUMAN; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

BREAST CANCER; NEOADJUVANT TREATMENT; PATHOLOGIC COMPLETE RESPONSE; TUMOR SUBTYPE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84884707847     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.07.028     Document Type: Article

References (19)

1. Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. JNatl Cancer Inst 2005 Feb 2, 97(3):188-194.
2. Mieog J.S., van der Hage J.A., van de Velde C.J. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007 Apr 18, 2:CD005002. Review.
3. von Minckwitz G., Kümmel S., Vogel P., et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. JNatl Cancer Inst 2008 Apr 16, 100(8):552-562. German Breast Group.
4. von Minckwitz G., Blohmer J.U., Raab G., et al. Invivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005 Jan, 16(1):56-63. German Breast Group.
5. von Minckwitz G., Untch M., Blohmer J.U., et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. JClin Oncol 2012 May 20, 30(15):1796-1804.
6. Houssami N., Macaskill P., von Minckwitz G., Marinovich M.L., Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 2012 Dec, 48(18):3342-3354.
7. von Minckwitz G., Untch M., Nüesch E., et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011 Jan, 125(1):145-156.
8. Cortazar P., Zhang L., Untch M., et al. Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). Cancer Research December 15, 2012, 72(24, Suppl.3).
9. Huober J., von Minckwitz G., Denkert C., et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010 Nov, 124(1):133-140.
10. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010 Jan 30, 375(9712):377-384.
11. ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D. Available from: [accessed 04.05.13]. http://clinicaltrials.gov/show/NCT00490139.
12. Schneeweiss A., Chia S., Hickish T., et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA). Cancer Res December 15, 2011, 71(24, Suppl.3).
13. von Minckwitz G, Mamouhdian-Dekordi C, Loibl S, etal. Response characteristics and overall survival of 781 patients with triple-negative breast cancer - a meta-analysis on 7 German neoadjuvant studies. AACR Annual Meeting; 2013.
14. Neoadjuvant treatment of docetaxel, anthracycline and cyclophosphamide (TAC) versus docetaxel and cyclophosphamide (TC) in triple-negative or Her2 positive breast cancer. Available from: [accessed 04.05.13]. http://clinicaltrials.gov/show/NCT00912444.
15. von Minckwitz G., Eidtmann H., Rezai M., et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. NEngl J Med 2012 Jan 26, 366(4):299-309. German Breast Group, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast Study GroupsArbeitsgemeinschaft Gynäkologische Onkologie-Breast Study Groups.
16. Bear H.D., Tang G., Rastogi P., Geyer C.E., et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. NEngl J Med 2012 Jan 26, 366(4):310-320.
17. Cameron D., Brown J., Dent R., et al. Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. Cancer Res December 15, 2012, 72(24, Suppl.3).
18. Addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Available from: [accessed 04.05.13]. http://clinicaltrials.gov/show/NCT01426880.
19. Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery. Available from: [accessed 04.05.13]. http://clinicaltrials.gov/show/NCT00861705.